7648 U.S.

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 58045-U1(46453)

Total Pages in this Submission SEVENTY-TWO (72)

TO THE COMMISSIONER FOR PATENTS

Mail Stop Patent Application P.O. Box 1450 Alexandria, VA 22313-1450

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

EN	HANCI	G TREATMENT OF MDR CANCER WITH ADENOSINE A3 ANTAGONISTS	71. 116
			20°S
and in	vented b		35
PII	ER ANDI	EA BOREA, PIER GIOVANNI BARALDI, SHIH-FONG CHEN, AND EDWARD LEUNG	162
If a C	ONTINU	ATION APPLICATION, check appropriate box and supply the requisite information:	
	Continu	tion Divisional Continuation-in-part (CIP) of prior application No.:	
Whic	h is a:		
	Continu	tion Divisional Continuation-in-part (CIP) of prior application No.:	
•	h is a:		
	Continua	tion Divisional Continuation-in-part (CIP) of prior application No.:	
Enclo	osed are:		
		Application Elements	
1.	🗵 Fi	ng fee as calculated and transmitted as described below	
2.	⊠ Sr	ecification having 53 pages and including the following:	
		pages and including the following.	
	a. 🛚	Descriptive Title of the Invention	
	b. 🗖	Cross References to Related Applications (if applicable)	
	с. 🗆	Statement Regarding Federally-sponsored Research/Development (if applicable)	
	d. 🗀	Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix	
	. е. 🛚	Background of the Invention	
	f. ⊠	Brief Summary of the Invention	
		Brief Description of the Drawings (if filed)	. •
	g. ⊠		
	h. ⊠ _	Detailed Description	
	i. 🛚	Claim(s) as Classified Below	
	j. 🛛	Abstract of the Disclosure	

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 58045-U1(46453)

Total Pages in this Submission SEVENTY-TWO (72)

Application Elements (Continued)

3.	\boxtimes	Drav	ving(s) <i>(when ne</i>	ecessary as prescribed by	35 USC 113)		
	a.	\boxtimes	Formal	Number of Sheets	EIGHT (8)		
	b.		Informal	Number of Sheets			
4.		Oath	or Declaration				
	a.		Newly executed	l (original or copy)	Unexecuted	,	
	b.		Copy from a pri	or application (37 CFR 1.6	3(d)) (for continuation/divis	ional application only)	
	C.		With Power of A	Attorney 🔲 Without F	Power of Attorney		
	d.		_	INVENTOR(S) ent attached deleting invent 1.63(d)(2) and 1.33(b).	or(s) named in the prior a	application,	
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.					
6.		CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)					
7.		Application Data Sheet (See 37 CFR 1.76)					
8.		Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)					
	a.	Computer Readable Form (CRF)					
	b.	□ Specification Sequence Listing on:					
		i. CD-ROM or CD-R (2 copies); or					
		ii. 🔲 Paper					
	C.	☐ Statement(s) Verifying Identical Paper and Computer Readable Copy					
Accompanying Application Parts							
9.		Assignment Papers (cover sheet & document(s))					
10.		37 CFR 3.73(B) Statement (when there is an assignee)					
11.		English Translation Document (if applicable)					
12.		Information Disclosure Statement/PTO-1449					
13.	X	Preliminary Amendment					
14.	X	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)					
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)					
16.	X	Certificate of Mailing					
			First Class	Express Mail (Specify L	abel No.): EV342612245	SUS	

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

17. Additional Enclosures (please identify below):

Docket No. 58045-U1(46453)

Total Pages in this Submission SEVENTY-TWO (72)

Acc mpanying Application Parts (Continued)

	DUPLICATE COPY OF PAGE 4 OF THIS TRANSMITTAL LETTER; PATENT APPLICATION TITLE PAGE; AND CERTIFICATE OF EXPRESS MAIL.					
	Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)					
18.	Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.					
	Warning					

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 58045-U1(46453)

Total Pages in this Submission SEVENTY-TWO (72)

Fee Calculation and Transmittal

CLAIMS AS FILED						
For	#Filed	#Allowed	#Extra	F	Rate	Fee
T tal Claims	27	- 20 =	7	× \$	18.00	\$126.00
Indep. Claims	4	- 3 =	1	× \$	84.00	\$84.00
Multiple Dependent Claims (check if applicable)						\$0.00
					BASIC FEE	\$750.00
OTHER FEE (specify	OTHER FEE (specify purpose) \$0.00					
					TOTAL FILING FEE	\$960.00
 A check in the amount of \$960.00 to cover the filing fee is enclosed. The Director is hereby authorized to charge and credit Deposit Account No. 04-1105 as described below. □ Charge the amount of as filing fee. ☑ Credit any overpayment. ☑ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. □ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b). 						
Dated: JUNE 20, 2003		·	REO ED' P.O BO	G. NO.: 34 WARDS & D. BOX 916 STON, MA	ANGELL, LLP	

CUSTOMER NO.: 21874

..EV342612245US

CERTIFICATE OF MAPPHICANT(s): PIER AND	Docket No. 58045-U1(46453)						
Serial No. -	Filing Date HEREWITH						
Invention: ENHANCING	G TREATMENT OF MDR CAN	CER WITH ADENOSINE A3	ANTAGONISTS				
	I hereby certify that the following correspondence: NEW UTILITY PATENT APPLICATION AND RELATED PAPERS.						
L	(Identify type of correspondence)						
	is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37						
CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on							
JUNE 20, 2003 (Date) DONNA R. DAVIS (Typed or Printed Name of Person Mailing Correspondence) (Signature of Person Mailing Correspondence) EV342612245US							
("Express Mail" Mailing Label Number)							

Note: Each paper must have its own certificate of mailing.